It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach.
So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision.
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Nektar Therapeutics ( NKTR ). This healthcare sector stock has actually seen loss estimates narrowing down from a loss of 65 cents a share to a loss of 47 cents over the past month for the current fiscal. But that is not yet reflected in its price, as the stock gained only 2.7% over the same time frame.
You should not be concerned about the price remaining muted going forward. This year's expected earnings growth over the prior year is 64.5%, which should ultimately translate into price appreciation.
And if this isn't enough, NKTR currently carries a Zacks Rank #2 (Buy) which further underscores the potential for its outperformance (See the performance of Zacks' portfolios and strategies here: About Zacks Performance ).
So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Nektar Therapeutics. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for NKTR and that now might be an interesting buying opportunity.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report